The PPI Pitfall:
 |
| PPIs' efficacy is influenced by the CYP2C19 enzyme, leading to variable drug metabolism among patients. Extensive metabolizers may not achieve optimal anti-secretory effects with standard doses due to differences in drug processing.1 |
 |
| CYP2C19 polymorphism contributes to variability in both the pharmacokinetics (drug metabolism) and pharmacodynamics (drug effects) of PPIs, leading to inconsistent treatment outcomes.2 |
VONO prazan: Overcoming PPI Limitations With Consistent Efficacy
| Minimal CYP2C19 Influence: Primarily metabolized by CYP3A4 with minimal CYP2C19 involvement, reducing the impact of CYP2C19 polymorphisms and leading to more predictable effects1 |  |
Consistent drug Exposure: Vonoprazan’s plasma concentrations are low enough to minimally affect CYP enzymes, resulting in fewer drug interactions2 |
Vono-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
